Drug Coated Balloon PEPCAD Japan SVD

Product Quick Finder

Choose a category or subcategory

SeQuent® Please vs. POBA (SeQuent® NEO) in small vessel de novo lesions

A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel disease

Funatsu A et al. Clin. Res. Cardiol. 2017; 106(10): 824-32

Key Findings

TVF was low for treatment of SVD with DCB. In addition, LLL was observed significantly more frequent in the DCB group in comparison to the POBA group.


Design: Randomized | Open-label | Prospective | Multicenter | Superiority (test for difference)

Indication: De novo

Main patient inclusion criterion: Reference vessel diameter ≤ 2.75 mm, ≥ 2 mm

Primary endpoint: TVF @ 6-month follow-up. Components of TVF:

  • Cardiac death: Death due to target vessel
  • MI: Creatine phosphokinase (CPK) elevation C3 times the normal value in addition to continuous chest symptoms and electrocardiogram changes due to target vessel
  • Composite events: Revascularization of target vessel (PCI or CABG)

Secondary endpoints:

  • TLR @ 6-month follow-up: Ischemia-driven if the lesion revealed restenosis (DS ≥ 50) associated with symptom or presence of ischemia, or if lesion diameter stenosis > 70% (by core laboratory QCA), even in the absence of clinical or functional ischemia
  • LLL @ 6-month follow-up

DAPT: 6 months


Patients: In total, 135 patients were enrolled and randomized into a DCB group and POBA group with a ratio of 2:1. Some patients were excluded from the trial due to unsuccessful treatment, consent withdrawal and protocol violation. Follow-up was performed in 88 patients from the DCB group and in 39 patients from the POBA group.

Baseline characteristics: The two treatment groups were well balanced. Apart from a higher proportion of diabetes mellitus in the DCB group, there were no statistically significant differences between the two treatment groups.

Primary endpoints: TVF was low in the DCB group

n = 88
n = 39
TVF 3.4 % 10.3 % 0.20
Cardiac death 0 % 0 % -
MI 0 % 0 % -
TLR 2.3 % 10.3 % 0.07

Secondary endpoints:

  DCB POBA p-value
Clinical follow-up 
No. of patients 88 39 -
TLR 2.3 % 10.3 % 0.07
Angiographic follow-up
No. of lesions 103 43 -
LLL 0.01 ± 0.31 mm 0.32 ± 0.34 mm < 0.01
B. Braun Melsungen AG
Sieversufer 8
12359 Berlin